文献速递腹部介入CTMR

肝细胞癌经动脉化疗栓塞后影像学肿瘤反应标准的成本效益分析

Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization.
PubMed 文献 · J Am Coll Radiol · 2021-01-20

本研究采用马尔可夫决策分析模型,从支付方角度比较qEASL、RECIST和mRECIST三种肿瘤影像学反应标准在肝细胞癌经动脉化疗栓塞后的成本效益。基础病例计算显示qEASL为优势策略,效果最高(1.06 QALY),预期成本最低(451,773美元),在多数迭代中比RECIST和mRECIST更具成本效益。

要点

  • qEASL为优势策略,效果1.06 QALY,成本451,773美元,均优于mRECIST和RECIST。
  • qEASL在71.50%的迭代中比RECIST更具成本效益,在69.26%的迭代中比mRECIST更具成本效益。
  • 单因素敏感性分析显示qEASL额外成本低于9,994美元时仍具成本效益。

核心结论

  • qEASL是肝细胞癌经动脉化疗栓塞后最具成本效益的肿瘤反应评估标准,与RECIST和mRECIST相比可大幅节省成本。

研究设计与样本

  • 构建马尔可夫决策分析模型,从支付方角度纳入成本和结局。
  • 评估三种肿瘤影像学反应标准:qEASL、RECIST和mRECIST。
  • 输入参数源自关于经动脉化疗栓塞后肝肿瘤反应评估的最全面文献。
  • 进行了确定性和概率敏感性分析。

诊断标准与关键数值

  • qEASL效果为1.06 QALY,mRECIST为1.05 QALY,RECIST为1.02 QALY。
  • qEASL预期成本为451,773美元,mRECIST为460,489美元,RECIST为459,004美元。
  • qEASL在71.50%的10,000次迭代中比RECIST更具成本效益,在69.26%的迭代中比mRECIST更具成本效益。
  • 单因素敏感性分析显示qEASL额外成本超过9,994美元前仍具成本效益。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Several tumor response criteria on cross-sectional imaging have been used in hepatocellular cancer after locoregional, intra-arterial therapy. The cost implications of their efficacy and accuracy are not well established.

PURPOSE: To evaluate cost-effectiveness of quantitative European Association for Study of the Liver (qEASL) compared with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) response criteria.

MATERIALS AND METHODS: A Markov decision-analytic model was constructed, accounting for both costs and outcomes from a payor perspective. Three different tumor imaging response criteria were evaluated: (1) qEASL, (2) RECIST, and (3) mRECIST. Input parameters were derived from the most comprehensive literature available focusing on the assessment of liver tumor response after transarterial chemoembolization. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS: Base case calculation showed qEASL to be the dominant strategy, with the highest effectiveness (1.06 quality-adjusted life years (QALY), as compared with 1.05 QALY in mRECIST and 1.02 QALY in RECIST). The expected costs of qEASL, mRECIST, and RECIST were $451,773, $460,489, and $459,004, respectively. qEASL was more cost-effective than RECIST in 71.50% of the 10,000 iterations and mRECIST in 69.26% of the iterations. One-way sensitivity analysis varying the cost showed that qEASL remained cost-effective until its additional cost was above $9,994.

CONCLUSION: Our study demonstrates qEASL to be the most cost-effective tumor response assessment criterion, with substantial cost savings as compared with RECIST and mRECIST for patients with hepatocellular carcinoma after transarterial chemoembolization.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Wu X, Chapiro J, Malhotra A, et al. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization. J Am Coll Radiol. 2021. PMID: 33484726. doi:10.1016/j.jacr.2020.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。